Allelic Loss of Chromosome 18q and Prognosis in Colorectal Cancer

1994 ◽  
Vol 331 (4) ◽  
pp. 213-221 ◽  
Author(s):  
Jin Jen ◽  
Hoguen Kim ◽  
Steven Piantadosi ◽  
Zong-Fan Liu ◽  
Roy C. Levitt ◽  
...  
1998 ◽  
Vol 114 (6) ◽  
pp. 1180-1187 ◽  
Author(s):  
Eva Martínez-López ◽  
Albert Abad ◽  
Albert Font ◽  
Mariano Monzó ◽  
Isabel Ojanguren ◽  
...  

2007 ◽  
Vol 171 (5) ◽  
pp. 1509-1519 ◽  
Author(s):  
Do Youn Park ◽  
Hideo Sakamoto ◽  
Sandra D. Kirley ◽  
Shuji Ogino ◽  
Takako Kawasaki ◽  
...  

2012 ◽  
Author(s):  
Rebecca A. Burrell ◽  
Sarah E. McClelland ◽  
David Endesfelder ◽  
Andrew Rowan ◽  
Arne Schenk ◽  
...  

1999 ◽  
Vol 117 (4) ◽  
pp. 831-837 ◽  
Author(s):  
Antoni Castells ◽  
Yasushi Ino ◽  
David N. Louis ◽  
Vijaya Ramesh ◽  
James F. Gusella ◽  
...  

Cancer ◽  
1996 ◽  
Vol 77 (S8) ◽  
pp. 1688-1693
Author(s):  
Masahiro Watatani ◽  
Toshihiro Yoshida ◽  
Kosaku Kuroda ◽  
Shintaro Ieda ◽  
Masayuki Yasutomi

2006 ◽  
Vol 72 (5) ◽  
pp. 445-453 ◽  
Author(s):  
T. Clark Gamblin ◽  
Sydney D. Finkelstein ◽  
Neil Upsal ◽  
Jonathan D. Kaye ◽  
David Blumberg

Pathologic staging in colorectal adenocarcinoma (CA) is based on the concept that the timing of metastatic tumor spread is directly related to the depth of the primary tumor invasion. To evaluate the temporal sequence of CA metastasis, we performed microdissection mutational profiling at multiple microscopic sites of primary and metastatic CA specimens. Twenty-one cases of CA were selected from fixed-tissue archives. Primary tumors were microdissected at the deepest point of invasion. Comparative mutational profiling for different genomic loci [1p36(CCM = cutaneous malignant melanoma], 3p26(OGGI = 8 oxoguanine DNA glycosylase), 5q23 (APC, MCC = mutated in colorectal cancer), 9p21(p16/CDKN2A = cyclin-dependent kinase 2A), 10q23(PTEN = phosphatase and tensin homolog [mutated in multiple advanced cancers 1]), 12p12(K-ras-2 point mutation), 17p13(TP53), 18q25(DCC= deleted in colorectal cancer) was carried out on each microdissected tissue target using microsatellite loss of heterozygosity determination or DNA sequencing. All primary and metastatic sites of CA manifested acquired mutational change in 18 to 91 per cent of the genomic markers. In 15/21 (71%) cases, metastatic sites lacked a specific allelic loss seen in the corresponding primary tumor, indicating that the metastasis occurred before maximal depth of primary invasion. This was further supported by discordant mutational profiles between primary and secondary tumors, requiring divergent clonal evolution. This is the first report describing the temporal sequence and significance of sequential mutational acquisition in clinical tissue specimens with potential implications for a new molecular pathology approach to classify human cancer.


Sign in / Sign up

Export Citation Format

Share Document